Correction

Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9)

David S. Shulman, Kelly Klega, Alma Imamovic-Tuco, Andrea Clapp, Anwesha Nag, Aaron R. Thorner, Eliezer Van Allen, Gavin Ha, Stephen L. Lessnick, Richard Gorlick, Katherine A. Janeway, Patrick J Leavey, Leo Mascarenhas, Wendy B. London, Kieuhoa T. Vo, Kimberly Stegmaier, David Hall, Mark D. Krailo, Donald A. Barkauskas, Steven G. DuBois & 1 others Brian D. Crompton

Research output: Contribution to journalComment/debate

Abstract

The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced. In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).

Original languageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StatePublished - Jan 1 2019

Fingerprint

Ewing's Sarcoma
Osteosarcoma
DNA
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Correction : Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9). / Shulman, David S.; Klega, Kelly; Imamovic-Tuco, Alma; Clapp, Andrea; Nag, Anwesha; Thorner, Aaron R.; Van Allen, Eliezer; Ha, Gavin; Lessnick, Stephen L.; Gorlick, Richard; Janeway, Katherine A.; Leavey, Patrick J; Mascarenhas, Leo; London, Wendy B.; Vo, Kieuhoa T.; Stegmaier, Kimberly; Hall, David; Krailo, Mark D.; Barkauskas, Donald A.; DuBois, Steven G.; Crompton, Brian D.

In: British Journal of Cancer, 01.01.2019.

Research output: Contribution to journalComment/debate

Shulman, DS, Klega, K, Imamovic-Tuco, A, Clapp, A, Nag, A, Thorner, AR, Van Allen, E, Ha, G, Lessnick, SL, Gorlick, R, Janeway, KA, Leavey, PJ, Mascarenhas, L, London, WB, Vo, KT, Stegmaier, K, Hall, D, Krailo, MD, Barkauskas, DA, DuBois, SG & Crompton, BD 2019, 'Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9)', British Journal of Cancer. https://doi.org/10.1038/s41416-019-0424-7
Shulman, David S. ; Klega, Kelly ; Imamovic-Tuco, Alma ; Clapp, Andrea ; Nag, Anwesha ; Thorner, Aaron R. ; Van Allen, Eliezer ; Ha, Gavin ; Lessnick, Stephen L. ; Gorlick, Richard ; Janeway, Katherine A. ; Leavey, Patrick J ; Mascarenhas, Leo ; London, Wendy B. ; Vo, Kieuhoa T. ; Stegmaier, Kimberly ; Hall, David ; Krailo, Mark D. ; Barkauskas, Donald A. ; DuBois, Steven G. ; Crompton, Brian D. / Correction : Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9). In: British Journal of Cancer. 2019.
@article{f31efdcf143c4074a1a4b66518b227e6,
title = "Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9)",
abstract = "The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced. In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2{\%} (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0{\%} (95{\%} CI 40.5–75.0) compared to 80.8 (95{\%} CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).",
author = "Shulman, {David S.} and Kelly Klega and Alma Imamovic-Tuco and Andrea Clapp and Anwesha Nag and Thorner, {Aaron R.} and {Van Allen}, Eliezer and Gavin Ha and Lessnick, {Stephen L.} and Richard Gorlick and Janeway, {Katherine A.} and Leavey, {Patrick J} and Leo Mascarenhas and London, {Wendy B.} and Vo, {Kieuhoa T.} and Kimberly Stegmaier and David Hall and Krailo, {Mark D.} and Barkauskas, {Donald A.} and DuBois, {Steven G.} and Crompton, {Brian D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1038/s41416-019-0424-7",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Correction

T2 - Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group (British Journal of Cancer, (2018), 119, 5, (615-621), 10.1038/s41416-018-0212-9)

AU - Shulman, David S.

AU - Klega, Kelly

AU - Imamovic-Tuco, Alma

AU - Clapp, Andrea

AU - Nag, Anwesha

AU - Thorner, Aaron R.

AU - Van Allen, Eliezer

AU - Ha, Gavin

AU - Lessnick, Stephen L.

AU - Gorlick, Richard

AU - Janeway, Katherine A.

AU - Leavey, Patrick J

AU - Mascarenhas, Leo

AU - London, Wendy B.

AU - Vo, Kieuhoa T.

AU - Stegmaier, Kimberly

AU - Hall, David

AU - Krailo, Mark D.

AU - Barkauskas, Donald A.

AU - DuBois, Steven G.

AU - Crompton, Brian D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced. In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).

AB - The authors have noticed that the final paragraph of the Results section contains errors in the number of patients involved. The correct number of patients is included in the text below. These errors do not affect the Figure referenced. In osteosarcoma, we focused on 8q gain as a specific biological feature of interest. Among the 41 patients with detectable ctDNA in the osteosarcoma cohort, 8q gain was detected in 73.2% (30/41). The 3-year EFS for patients with 8q gain (n = 30) in ctDNA was 60.0% (95% CI 40.5–75.0) compared to 80.8 (95% CI 42.4–94.9) in patients without 8q gain (n = 11) in ctDNA (p = 0.18; Fig. 3).

UR - http://www.scopus.com/inward/record.url?scp=85063149311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063149311&partnerID=8YFLogxK

U2 - 10.1038/s41416-019-0424-7

DO - 10.1038/s41416-019-0424-7

M3 - Comment/debate

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -